Vaxcyte, Inc. PCVX
NASDAQ · United States · Health Technology
$56.62-0.28 (-0.49%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Vaxcyte's (PCVX) upcoming data readout for its investigational pneumococcal conjugate vaccine VAX-31
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Vaxcyte (PCVX) has drawn fresh attention after recent trading left the share price at US$58.13, with short term performance mixed and longer term returns still materially positive for existing holders. Recent trading has cooled some of Vaxcyte’s earlier momentum, with the share price down over the past month but still showing a 90-day share price return of 11.87% and a 1-year total shareholder return of 73.68%, which points to strong longer term sentiment. Scan how Vaxcyte’s recent run...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.